Healthcare Business

AtheroGenics Gets Knocked Down

Drug developer AtheroGenics (AGIX) said Wednesday its failed heart-drug candidate showed signs it may be effective as an oral anti-diabetic drug

The company is currently recruiting patients for a Phase III clinical trial on the drug candidate

Wall St. seemed to think that the news put any recovery at the company almost out of reach. Its shares dropped 19% to $2.44. They have a 52-week high of $15.70.

Douglas A. McIntyre